Please assess the completion status of the following clinical trial:

Trial Title: Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Individuals aged 18-75 years~* Individuals who had at least one and no more than 6 histologically confirmed CRAs removed within 6 months before recruitment~* Individuals who are able to swallow pills~* Individuals who voluntarily sign the consent form after being fully informed and understanding the purpose and procedure of this study, characters of the disease, effect of medication, methods of related examinations, and potential risk/benefits of the study 4.2 Exclusion criteria~* Individuals whose adenoma was not completely removed during previous colonoscopy~* Individuals with a history of familial adenomatous polyposis (FAP) or hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome)~* Individuals who are taking regularly aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), cyclo-oxygenase 2 (COX2) inhibitors, calcium or vitamin D~* Individuals with a history of subtotal/total gastrectomy or partial bowel resection~* Individuals who are intolerant to another colonoscopy examination~* Individuals who are hypersensitive or intolerant to the drugs~* Individuals with severe heart, liver or kidney disease, or any cancer history~* Individuals presenting severe constipation~* Pregnant women, women during breast-feeding period, or women with expect pregnancy~* Individuals with mental diseases who are not able to cooperate~* Individuals who are involved in designing, planning or performing this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Berberine hydrochloride (Type: EXPERIMENTAL): supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
- placebo (Type: PLACEBO_COMPARATOR): identical-appearing placebo supplements for 2-3 years

Based on this trial design, predict the completion outcome and termination type (if applicable).